5:44 PM
 | 
Feb 26, 2013
 |  BC Extra  |  Company News

Concert, Jazz partner for sodium oxybate compounds

Concert Pharmaceuticals Inc. (Lexington, Mass.) granted Jazz Pharmaceuticals plc (NASDAQ:JAZZ) exclusive, worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate compounds, including lead compound C-10323. Jazz will be responsible for development, and Concert will receive an undisclosed upfront payment and is eligible for up to $120 million in milestones, plus tiered royalties....

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >